TAS2R38 and COVID-19: At first, we analyzed TAS2R38 DNAm profiling in a group of 44 COVID-19-positive patients and 7 participants after the infection (post-COVID-19), who were also included to evaluate the DNAm reversibility after the cessation of the exposition to infection.